I. Benjamin Gaddie, OD, FAAO, summarized the best forms of treating and managing demodex blepharitis.
During the Southeastern Educational Congress of Optometry (SECO) 2025 meeting held from February 27 to March 2, 2025, in Atlanta, Georgia, I. Benjamin Gaddie, OD, FAAO, chief technology officer at Keplr Vision, spoke about demodex blepharitis, how best to treat it, and how accessible that treatment is for patients.
This transcript has been lightly edited for clarity; captions were auto-generated.
Transcript
What are the best ways of treating and managing demodex blepharitis?
First of all, making the diagnosis is the seminal event in demodex blepharitis, and it's really the easiest thing I think there is in all of eye care to do. You simply have the patient look down at the slit lamp and you're looking at the base of the lashes for collarettes. Once you see a collarette that is pathogenomic for demodex blepharitis, really no other diagnostic test is needed. When I have that, I now have an FDA-approved drug in Xdemvy, which is lotilaner [ophthalmic solution], and we use that twice a day for 6 weeks, and nearly 8 out of 10 patients get down to 10 or less colarettes from a baseline of around 150. It works quickly. It works well. It's safe and well tolerated, so it's an easy drug to reach for. I don't have to worry about if they're going to be able to tolerate it, or if it's even going to work
How can patients access treatment should they need it? How accessible is treatment?
With lotilaner, Xdemvy, from TarsusRX, the access program is a little nuanced. It takes some practice to sort through it, but once you do it's a really simple process. In our area, we use a specialty Walgreens. They only do eye and ear, nose, and throat drugs, and they know how to access the patient programs that allow for the buy down of the co-pays and the various methods to get the drug at an accessible price. I would say today, 85% of my patients are getting the drug for $60 or less. But it does take some work on the doctor side, prior authorizations, and just communicating with the patient.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More